DE602004013355D1 - Verwendung des proteins spee als marker für brustkrebs - Google Patents

Verwendung des proteins spee als marker für brustkrebs

Info

Publication number
DE602004013355D1
DE602004013355D1 DE602004013355T DE602004013355T DE602004013355D1 DE 602004013355 D1 DE602004013355 D1 DE 602004013355D1 DE 602004013355 T DE602004013355 T DE 602004013355T DE 602004013355 T DE602004013355 T DE 602004013355T DE 602004013355 D1 DE602004013355 D1 DE 602004013355D1
Authority
DE
Germany
Prior art keywords
breast cancer
spee
marker
diagnosis
protein spee
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004013355T
Other languages
English (en)
Other versions
DE602004013355T2 (de
Inventor
Gabriele Pestlin
Peter Berndt
Marie-Luise Hagmann
Johann Karl
Hanno Langen
Norbert Wild
Werner Zolg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of DE602004013355D1 publication Critical patent/DE602004013355D1/de
Application granted granted Critical
Publication of DE602004013355T2 publication Critical patent/DE602004013355T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/9116—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • G01N2333/91165—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5) general (2.5.1)
    • G01N2333/91171—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5) general (2.5.1) with definite EC number (2.5.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602004013355T 2003-10-15 2004-10-15 Verwendung des proteins spee als marker für brustkrebs Active DE602004013355T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03023508 2003-10-15
EP03023508 2003-10-15
PCT/EP2004/011595 WO2005040804A1 (en) 2003-10-15 2004-10-15 Use of protein spee as a marker for breast cancer

Publications (2)

Publication Number Publication Date
DE602004013355D1 true DE602004013355D1 (de) 2008-06-05
DE602004013355T2 DE602004013355T2 (de) 2009-05-20

Family

ID=34486069

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004013355T Active DE602004013355T2 (de) 2003-10-15 2004-10-15 Verwendung des proteins spee als marker für brustkrebs

Country Status (8)

Country Link
US (1) US20060257951A1 (de)
EP (1) EP1676134B1 (de)
JP (1) JP4292208B2 (de)
AT (1) ATE393393T1 (de)
CA (1) CA2536536A1 (de)
DE (1) DE602004013355T2 (de)
ES (1) ES2305866T3 (de)
WO (1) WO2005040804A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE418737T1 (de) * 2003-08-08 2009-01-15 Hoffmann La Roche Verwendung des proteins spermidinsynthase (spee) als marker für kolorektalkarzinom
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
WO2008107201A1 (en) * 2007-03-08 2008-09-12 Roche Diagnostics Gmbh Use of slim-1 in the assessment of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046471A2 (en) * 2000-12-08 2002-06-13 Board Of Regents, The University Of Texas System Methods and compositions for the identification, assessment and therapy of human cancers
MXPA03006617A (es) * 2001-01-24 2004-12-02 Protein Design Labs Inc Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
AU2003227071A1 (en) * 2002-03-14 2003-09-22 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis
ATE418737T1 (de) * 2003-08-08 2009-01-15 Hoffmann La Roche Verwendung des proteins spermidinsynthase (spee) als marker für kolorektalkarzinom

Also Published As

Publication number Publication date
EP1676134B1 (de) 2008-04-23
CA2536536A1 (en) 2005-05-06
EP1676134A1 (de) 2006-07-05
DE602004013355T2 (de) 2009-05-20
US20060257951A1 (en) 2006-11-16
ES2305866T3 (es) 2008-11-01
WO2005040804A1 (en) 2005-05-06
ATE393393T1 (de) 2008-05-15
JP4292208B2 (ja) 2009-07-08
JP2007507694A (ja) 2007-03-29

Similar Documents

Publication Publication Date Title
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
ATE554389T1 (de) Apex als marker für lungenkrebs
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
NO339224B1 (no) Bedrede immunprøvemetoder
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
MX2010000971A (es) Sistema y metodos que determinan concentracion de analito utilizando amperometria resuelta en tiempo.
ATE438856T1 (de) Biomarker für eierstockkrebs: mit ctap3 verwandte proteine
EP1930445A4 (de) Kit und verfahren zum nachweis von urothelkarzinom
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
CY1112553T1 (el) Ανοσοπροσδιορισμοι υψηλης ευαισθησιας και κιτια για τον προσδιορισμο πεπτιδιων και πρωτεϊνων βιολογικου ενδιαφεροντος
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
DE602006015702D1 (de) Unterscheidung zwischen baktiereller meningitis und viraler meningitis
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
ATE393393T1 (de) Verwendung des proteins spee als marker für brustkrebs
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
WO2010000467A8 (en) Asc as a marker for lung cancer
ATE359516T1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs
ATE418737T1 (de) Verwendung des proteins spermidinsynthase (spee) als marker für kolorektalkarzinom
DE602005010548D1 (de) Verbessertes verfahren zur diagnose des akuten koronarsyndroms
ATE410691T1 (de) Verwendung des proteins proteasome aktivator untereinheit 3 als marker für kolorektale karzinome
ATE531822T1 (de) Diagnose von prostatakrebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition